Abstract
Natural killer (NK) activity is a poorly understood component of the immune system, generally identified as the ability to kill certain tumour cells1,2. Perhaps the most controversial issue has been the lineage to which cells displaying this activity belong. Extensive studies of surface antigens on cells with NK activity in both mouse and man have led to enigmatic results, such cells apparently bearing markers of both T-cell (Thy-1 and E receptor) and myeloid (Mac-1 and OKM1) lineages3–6. A fresh approach to this problem would be to take cells of known lineage and test whether they express, or could be induced to express, NK cell function. Using this approach we show here that monoclonal cytotoxic T lymphocyte (CTL) lines can be induced, by culture in high concentrations of spleen cell supernatant, to express a new lytic activity apparently identical with that of splenic cells NK activity. Preliminary evidence implicates both interleukin-2(IL-2) and interferon (IFN) as mediators of this phenomenon. These findings clearly demonstrate that cells of T cell lineage have the capacity to express NK activity.
References
- 1.Herberman RB, Holden HT. Adv. Cancer Res. 1978;27:305–377. doi: 10.1016/S0065-230X(08)60936-7. [DOI] [PubMed] [Google Scholar]
- 2.Kiessling R, Haller O. Contemp. Top. Immunobiol. 1978;8:171–225. doi: 10.1007/978-1-4684-0922-2_6. [DOI] [PubMed] [Google Scholar]
- 3.Herberman RB, Nunn ME, Holden HT. J. Immun. 1978;121:304–309. [PubMed] [Google Scholar]
- 4.West WM, Cannon GB, Herberman RB. J. Immun. 1977;118:355–361. [PubMed] [Google Scholar]
- 5.Holmberg LA, Springer TA, Ault KA. J. Immun. 1981;127:1792–1799. [PubMed] [Google Scholar]
- 6.Zarling JM, Kung PC. Nature. 1980;288:394–396. doi: 10.1038/288394a0. [DOI] [PubMed] [Google Scholar]
- 7.Glasebrook AL, Fitch FW. J. exp. Med. 1980;151:876–895. doi: 10.1084/jem.151.4.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bonavida B, Bradley TP. Transplantation. 1976;21:94–102. doi: 10.1097/00007890-197602000-00002. [DOI] [PubMed] [Google Scholar]
- 9.Sitkovsky MV, Pasternak MS, Eisen M. J. Immun. 1982;129:1372–1376. [PubMed] [Google Scholar]
- 10.Gidlund M, Orn A, Wigzell H, Senik A, Gresser I. Nature. 1978;273:273–761. doi: 10.1038/273759a0. [DOI] [PubMed] [Google Scholar]
- 11.Henney CS, Kuribayashi K, Kern DE, Gillis S. Nature. 1982;291:335–338. doi: 10.1038/291335a0. [DOI] [PubMed] [Google Scholar]
- 12.Dennert G, Yogeeswaran G, Yamagata S. J. exp. Med. 1981;153:544–556. doi: 10.1084/jem.153.3.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Nabel G, Bucalo LR, Allard J, Wigzell H, Cantor H. J. exp. Med. 1981;153:1582–1591. doi: 10.1084/jem.153.6.1582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Brooks CG, Kuribayashi K, Sale GE, Henney CS. J. Immun. 1982;128:2326–2335. [PubMed] [Google Scholar]
- 15.Handa K, Suzuki R, Matsui H, Simizu Y, Kumagai K. J. Immun. 1983;130:988–992. [PubMed] [Google Scholar]
- 16.Brooks CG, Urdal D, Henney CS. Immun. Rev. 1983;72:43–72. doi: 10.1111/j.1600-065X.1983.tb01072.x. [DOI] [PubMed] [Google Scholar]
- 17.Klein E. Immun. Today. 1980;1:iv–vi. [Google Scholar]
- 18.Brooks, C. G., Burton, R. C., Pollack, S. B. & Henney, C. S. J. Immun.131 (in the press). [PubMed]
- 19.Click RE, Benck L, Alter BJ. Cell. Immun. 1972;3:264–276. doi: 10.1016/0008-8749(72)90165-7. [DOI] [PubMed] [Google Scholar]
- 20.Cikes M, Friberg S, Klein G. J. natn. Cancer Inst. 1973;50:347–362. doi: 10.1093/jnci/50.2.347. [DOI] [PubMed] [Google Scholar]
- 21.Durdik JM, Beck BN, Clark EA, Henney CS. J. Immun. 1980;125:683–688. [PubMed] [Google Scholar]
- 22.Dunn TB, Potter MJ. J. natn. Cancer Inst. 1957;180:587–603. [PubMed] [Google Scholar]
- 23.Gorer PA. Br. J. Cancer. 1950;4:372–392. doi: 10.1038/bjc.1950.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Gillis Immun. Rev. 1982;63:167–208. doi: 10.1111/j.1600-065X.1982.tb00415.x. [DOI] [PubMed] [Google Scholar]